Belite Bio reports Phase 3 DRAGON tinlarebant cuts Stargardt lesion growth 35.7%
PUBT · 4d ago
Share
Listen to the news
- Belite Bio scheduled oral presentation May 22, 2026 at Retina China 2026 covering previously disclosed topline results from Phase 3 DRAGON trial of tinlarebant in Stargardt disease type 1.
- Study readout showed tinlarebant slowed disease progression versus placebo, supporting clinical benefit in adolescent Stargardt patients.
- Safety profile was described as generally tolerable, consistent with drug mechanism.
- Belite Bio initiated rolling FDA submission in April 2026, positioning tinlarebant for potential US approval review in STGD1.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief on May 15, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved